Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO, June 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that they have engaged in a preclinical agreement through the OncoSec Technology Access Program (TAP) with Jounce Therapeutics, Inc., (NASDAQ: JNCE) Cambridge, MA, a company focused on the …
Tag Archives: Jounce Therapeutics
June, 2017
January, 2017
-
4 January
Jounce Therapeutics Files for $75M IPO
CAMBRIDGE, Mass., January 3, 2017 –Jounce Therapeutics, a clinical-stage immuno-oncology company, has filed an initial public offering through which it hopes to raise $75 million in 2017. The Cambridge, MA-based company was founded in 2012 and employs a two-pronged approach to therapy development: using a translational science platform that targets …
July, 2016
-
19 July
Celgene and Jounce Therapeutics Enter Cancer Immunotherapy Collaboration
CAMBRIDGE, Mass., July 19, 2016 – Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced a global strategic collaboration with Celgene Corporation (NASDAQ: CELG) focused on developing and commercializing innovative immuno-oncology treatments for patients with cancer. …
April, 2015
-
23 April
Jounce Therapeutics Secures $56 Million to Advance Novel Immuno-Oncology Drugs
Two-year old biotech, Jounce Therapeutics Inc. announced that it has raised a $56 million Series B round, which will be used to develop new immuno-oncology drugs. Unlike many drugmakers designing therapies that make it harder for cancer to hide from the immune system, Jounce is studying the therapeutic potential of …